Table 10.
Predictive risk of CCA recurrence in early stage patients using either the combination of soluble CSC markers, CD44, CD44v6, CD44v8-10 and EpCAM or the combination of soluble CSC markers with CA19-9
| Comparative prediction | OR | p | OR | p |
|---|---|---|---|---|
| Crude | (95% CI) | Adjusted | (95% CI) | |
| Post-operative recurrence | ||||
| Levels of all markers ≥ cut-offa | ||||
| Nob (46) | 1 | 0.004 | 1 | 0.006 |
| Yes (14) | 7.08 | (1.867–26.870) | 7.39 | (1.760–31.071) |
| CA19-9 ≥ 37 U/mL + Levels of all markers ≥ cut-off | ||||
| No + No and Yes + No and No + Yes (36) | 1 | 0.005 | 1 | 0.011 |
| Yes + Yes (9) | 12.25 | (2.114–70.986) | 15.28 | (1.879–124.320) |
OR odds ratio, OR adjusted odds ratio adjusted for age and sex statistical analysis, 95% CI 95% confidence interval
aLevels of all markers: levels of CD44, CD44v6, CD44v8-10 and EpCAM
bNo: patients with at least one of marker lower than a designated cut-off